Liposomal Drug Delivery to the Central Nervous System

Nieto-Montesinos, Rita

doi:10.5772/intechopen.70055

Cited by 12 publications

(10 citation statements)

References 136 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, they have been extensively used in formulations as nanocarriers for the effective delivery of drugs, vaccines, proteins, enzymes, nucleic acids [70], and imaging agents [73]. Recent works have demonstrated their potential to deliver therapeutic and diagnostic agents to the brain, across the blood–brain barrier, through passive or active targeting [74].…”

Section: Neurotoxicity Of Nanomaterialsmentioning

confidence: 99%

Neurotoxicity of Nanomaterials: An Up-to-Date Overview

et al. 2019

View full text Add to dashboard Cite

The field of nanotechnology, through which nanomaterials are designed, characterized, produced, and applied, is rapidly emerging in various fields, including energy, electronics, food and agriculture, environmental science, cosmetics, and medicine. The most common biomedical applications of nanomaterials involve drug delivery, bioimaging, and gene and cancer therapy. Since they possess unique properties which are different than bulk materials, toxic effects and long-term impacts on organisms are not completely known. Therefore, the purpose of this review is to emphasize the main neurotoxic effects induced by nanoparticles, liposomes, dendrimers, carbon nanotubes, and quantum dots, as well as the key neurotoxicology assays to evaluate them.

show abstract

Section: Neurotoxicity Of Nanomaterialsmentioning

confidence: 99%

Neurotoxicity of Nanomaterials: An Up-to-Date Overview

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Furthermore, liposomes have demonstrated their potential in neurological applications as they can cross the BBB through passive or active targeting and deliver the appropriate quantity of therapeutic and diagnosis agents to the brain [47]. The main paths for liposomes to reach the brain parenchyma include the adsorption-mediated transcytosis, the receptor-mediated endocytosis, and the disruption of the BBB through external forces [48].…”

Section: Nanocarriers For Brain Targetingmentioning

confidence: 99%

Neuronanomedicine: An Up-to-Date Overview

et al. 2019

View full text Add to dashboard Cite

The field of neuronanomedicine has recently emerged as the bridge between neurological sciences and nanotechnology. The possibilities of this novel perspective are promising for the diagnosis and treatment strategies of severe central nervous system disorders. Therefore, the development of nano-vehicles capable of permeating the blood–brain barrier (BBB) and reaching the brain parenchyma may lead to breakthrough therapies that could improve life expectancy and quality of the patients diagnosed with brain disorders. The aim of this review is to summarize the recently developed organic, inorganic, and biological nanocarriers that could be used for the delivery of imaging and therapeutic agents to the brain, as well as the latest studies on the use of nanomaterials in brain cancer, neurodegenerative diseases, and stroke. Additionally, the main challenges and limitations associated with the use of these nanocarriers are briefly presented.

show abstract

“…This is achievable owing to their small size (1-1,000 nm), surface charge, high surface to volume ratio (Singh and Lillard, 2009). In CNS delivery, the BBB barrier presents a great obstacle for the nanoformulations targeting neuronal systems (Misra et al, 2003). Altering the surface characteristics of nanformulations enables crossing the BBB by avoiding phagocytic opsonization, thus enhancing the drug levels in the brain (Gidwani and Singh, 2014).…”

Section: Elevated Plasma Total Homocysteine Levelsmentioning

confidence: 99%

Nanocarriers for Alzheimer’s disease: Research and patent update

Pathak¹,

Kiran²,

Porwal³

et al. 2021

J Appl Pharm Sci

View full text Add to dashboard Cite

Alzheimer's disease (AD) is one of the most progressive neurodegenerative disorders resulting in cognitive and behavioral impairment in individuals beyond 65 years of age. It is distinguished by deposits of extracellular amyloidal protein intracellular and neurofibrillary tangles resulting in senile plaques. Significant advancement has been made in AD therapeutics; however, most of the treatment approaches are based on attenuating symptoms, implying that AD is still an insolvable neurodegenerative illness. Though an enormous number of drug moieties were already screened for different molecular targets of AD, only few of them (N-methyl D-aspartate receptor antagonists and acetylcholinesterase inhibitors) are currently implied for efficacious clinical treatment. Though these medications slow down the development of the disorder and give symptomatic relief; yet they are unsuccessful in achieving a proven cure. Nonetheless, targeted drug delivery of these medications to the Central nervous system (CNS) manifested various restrictions like meager solubility, lower bioavailability along with diminished effectiveness because of the bloodbrain barrier. Recent developments in nanotechnology present chances to overcome such limitations in targeting. Various nanocarriers have been researched that offer promising targeting capabilities. This review aims to provide an update on various dosage forms based on nanotechnology aimed for AD therapeutics, the patents on nanocarriers for AD and clinical trials on AD drugs.

show abstract

Liposomal Drug Delivery to the Central Nervous System

Cited by 12 publications

References 136 publications

Neurotoxicity of Nanomaterials: An Up-to-Date Overview

Neurotoxicity of Nanomaterials: An Up-to-Date Overview

Neuronanomedicine: An Up-to-Date Overview

Nanocarriers for Alzheimer’s disease: Research and patent update

Contact Info

Product

Resources

About